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1
IODO-NONOXYNOL-9-DERIVATIVES AND
METHODS FOR THEIR USE
TECHNICAL FIELD
The present invention relates to mono- and di-iodinated
nonoxynol-9-derivatives and methods for their use.

BACKGROUND ART

Nonionic surfactants are a preferred class of active agents
for use in spermicidal formulations. For example, the non
ionic surfactant nonoxynol-9 is a component in many com

10

mercially available spermicidal formulations. Spermicidal
formulations are administered in the vaginal cavity for their
local activity against human spermatoZoa. It has been theo

Wherein R is a carbon atom containing moiety having at least
6 carbon atoms, Q is H or I, and n=1—25.
Another aspect of the present invention is a pharmaceu

tical composition comprising a compound of formula (I),
and a pharmaceutically acceptable carrier.
15

A further aspect of the present invention is a method for

preventing conception, the method comprising the step of

riZed that spermicidal agents exert their activity by inserting
a hydrophobic moiety into the spermatoZoan cell membrane.

administering an effective amount of a compound of formula

Upon insertion, the spermicidal agents disrupt the integrity

(I).

of the cell membrane. This leads to an osmotic imbalance in

Yet another aspect of the present invention is a method for
reducing or preventing transmission of a sexually transmit

the cell and, ultimately, cell lysis, thereby preventing sperm
from fertiliZing the egg and impeding conception.

ted disease, the method comprising the step of administering
an effective amount of a compound of formula

Mixed experimental evidence exists as to Whether non

One more aspect of the present invention relates to plastic

ionic surfactants used in spermicides kill human immuno

de?ciency virus (HIV). In vitro experiments reveal that
nonoxynol-9 inactivates HIV-1 completely. The inactivation

25

and paper products coated With compounds of formula
An additional aspect of the present invention is a process
for preparing a compound of formula (I), the process com
prising the steps of reacting thallium tri?uoroacetate With a

may be through a mechanism similar to that proposed for the

reduction of sperm motility. The hydrophobic portion of the
nonoxynol-9 molecule may associate With hydrophobic

compound of formula:

fragments on the surface of the HIV virion leading to the

derangement of the viral envelope and inactivation. The
hydrophobic moieties of the virion include constituent
lipids, sterols and proteins of the host cell membrane from
Which the viral envelope stems in addition to viral proteins.

35

Nonoxynol-9 suffers from a number of draWbacks. For

Wherein R and n are as de?ned above to form an electro

example, in vivo clinical trials of products containing

philic thallium intermediate, and iodinating the intermedi

nonoxynol-9 do not shoW clear evidence of protection
against HIV infection. Certain studies indicated that HIV
infection rates Were essentially equal When a population of

ate.

become readily apparent to those skilled in this art from the

Women used vaginal contraceptives containing nonoxynol-9

folloWing detailed description, Wherein only the preferred

or a placebo. Furthermore, vaginal irritation appears to

embodiment of the present invention is shoWn and

Additional advantages of the present invention Will

increase With increased dose of nonoxynol-9.
45

A need exists for compounds Which are more effective at
loWer doses, and Which can achieve equal or greater con

described, simply by Way of illustration of the best mode
contemplated for carrying out the present invention. As Will
be realiZed, the present invention is capable of other and
different embodiments, and its several details are capable of
modi?cations in various obvious respects, all Without

traceptive and anti-HIV ef?cacy With less irritation.

departing from the present invention. Accordingly, the draW

DISCLOSURE OF THE INVENTION

ings and description are to be regarded as illustrative in

An advantage of the present invention is the provision of
compounds Which are effective to prevent conception.
Another advantage of the present invention is the provi

nature, and not as restrictive.

BRIEF DESCRIPTION OF DRAWINGS

sion of compounds Which are effective to reduce or prevent 55

transmission of sexually transmitted diseases.
Additional advantages of the present invention Will be set
forth in part in the description Which folloWs and in part Will
become apparent to those having ordinary skill in the art

FIG. 1 illustrates an abbreviated synthetic pathWay for

mono-iodination of nonoxynol-9 according to the present
invention.
FIG. 2 illustrates a reverse-phase HPLC chromatogram of

mono-iodinated nonoxynol-9 reaction product (Waters C-18

upon examination of the folloWing or may be learned from

analytical column, mobile phase=methanol:Water (80:20)

the practice of the present invention. The advantages of the

obtained by the present invention.

present invention may be realiZed and obtained as particu

larly pointed out in the appended claims.
According to the present invention, the foregoing and
other advantages are achieved in part by a compound of the
formula:

FIG. 3 illustrates the aromatic region of H-NMR of

mono-iodinated nonoxynol-9 (in CDCl3) according to the
65

present invention.
FIG. 4 illustrates the aromatic region of H-NMR of

nonoxynol-9 (in CDCl3).

US 6,281,251 B1
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loZenges and granules), dragees, capsules, pills, sponges,
creams, liquids, douches, gels, jellies, aerosol foams,

FIG. 5 illustrates an abbreviated synthetic pathway for

di-iodination of nonoxynol-9 according to the present inven
tion.
FIG. 6 illustrates the aromatic region of H-NMR of

impregnated tampons, ovules, controlled delivery device or

di-iodinated nonoxynol-9 (in CDCl3) according to the

“Pharmaceutical composition” means physically discrete
coherent portions suitable for medical administration.
“Pharmaceutical composition in dosage unit form” means
physically discrete coherent units suitable for medical
administration, each containing a daily dose or a multiple
(up to four times) or a sub-multiple (doWn to a fortieth) of
a daily dose of the active agent of the invention in associa

as a lubricant on, for example, a condom or a cap diaphragm.

present invention.
FIG. 7 illustrates a FAB mass spectral analysis for a

collected nonoxynol-9 (oligomer 7, n=7) fraction.
FIG. 8 illustrates a FAB mass spectral analysis for a

10

collected mono-iodinated nonoxynol-9 (oligomer 7, n=7)
fraction according to the present invention.

tion With a carrier and/or enclosed Within an envelope.
Whether the composition contains a daily dose, or for

FIG. 9 illustrates a FAB mass spectral analysis for

di-iodinated nonoxynol-9 (oligomers 1—17, n=1—17).

15

example, a half, a third or a quarter of a daily dose Will

depend on Whether the pharmaceutical composition is to be

DESCRIPTION OF THE INVENTION

administered once or, for example, tWice, three times or four

The present invention provides compounds of the for

times a day, respectively.

mula:

Advantageously, the compositions are formulated as dos

age units, each unit being adapted to supply a ?xed dose of
active ingredients. Tablets and capsules are examples of

preferred dosage forms according to the invention. It is only
25

necessary that the active ingredient constitute an effective
amount, i.e., such that a suitable effective dosage Will be

consistent With the dosage form employed in single or
multiple unit doses. The exact individual dosages, as Well as

Wherein R is a carbon atom containing moiety having at least
6 carbon atoms, Q is H or I and n=1—25.
The compounds of the present invention may be indi
vidual oligomers or mixtures thereof. In other Words, the
compounds of the present invention can be obtained from a
starting material Which is a multicomponent mixture of

daily dosages, are determined according to standard medical
principles under the direction of a physician.
The active agents can also be administered as

suspensions, solutions and emulsions of the active com
pound in aqueous or non-aqueous diluents, syrups, granu
lates or poWders. Diluents that can be used in pharmaceu
35

different oligomers having ethylene oxide chains With dif
ferent lengths, represented by “n” Which denotes the number
of ethylene oxide units. The iodinated compounds can be

also obtained from their respective oligomers of, for

example, nonoxynol-9 by utiliZing the iodination reaction

rolidone; (c) moisturiZing agents, e.g., glycerol; (d) disinte

described herein.
R can be any carbon atom containing moiety having at
least 6 carbon atoms. Examples of carbon atom containing

grating agents, e.g., agar-agar, calcium carbonate and

moieties include unsubstituted or substituted straight or 45

branched chain alkyl groups such as octyl and nonyl;

unsubstituted phenyl, biphenyl and naphthyl groups; substi
tuted and unsubstituted aryl groups; polycyclic groups,

alcohol, glycerol monostearate; (h) adsorptive carriers, e.g.,
The tablets, capsules and pills comprising the active agent
can have the customary coatings, envelopes and protective

di-iodinated (Q is I). The iodine may be, for example,
123-iodine, 125-iodine, 127-iodine and 131-iodine.

matrices, Which may contain opaci?ers. They can be so

n may range from 1—25, such as, from 4 to 15 and more
55

typically Water-insoluble. When n is 17—25, the compounds
are typically Water-soluble.
The compounds for use in the present invention can be
administered as a pharmaceutical composition. The pharma

constituted that they release the active ingredient only or
preferably in a particular part of the intestinal tract, possibly
over a period of time. The coatings, envelopes and protective
matrices may be made, for example, from polymeric sub
stances or Waxes.

The active ingredient can also be made up in microen
capsulated form together, With one or several of the above
mentioned diluents.
The pharmaceutical compositions Which are solutions and

ceutical compositions of the present invention comprise at
least one compound of formula (I), i.e., at least one active
agent, in combination With a pharmaceutical carrier or

excipients.
The pharmaceutical compositions can be in any form
suitable for oral administration, or for topical administration
to the vagina. Suitable forms include tablets (including

sodium bicarbonate; (e) agents for retarding dissolution,
e.g., paraf?n;
resorption accelerators, e.g., quaternary
ammonium compounds; (g) surface active agents, e.g., cetyl
kaolin and bentonite;
lubricants, e.g., talc, calcium and
magnesium stearate and solid polyethylene glycols.

alicyclic groups, etc.
The compounds may be mono-iodinated (Q is H) or

particularly, from 6—8. When n is 1—6, the compounds are

tical compositions (e.g., granulates) containing the active
compound adapted to be formed into tablets, dragees, cap
sules and pills include the folloWing: (a) ?llers and
extenders, e.g., starch, sugars, mannitol and silicic acid; (b)
binding agents, e.g., carboxymethyl cellulose and other
cellulose derivatives, alginates, gelatine and polyvinyl pyr

emulsions can, for example, contain the customary diluents,
65

such as dissolving agents and emulsi?ers. Speci?c non

limiting examples of such diluents are Water, ethyl alcohol,

isopropyl alcohol, ethyl carbonate, ethyl acetate, benZyl

US 6,281,251 B1
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alcohol, benZyl benZoate, propylene glycol, 1,3-butylene
glycol, dimethylformamide, oils (for example, ground nut

In addition, the present invention relates to a method for
reducing or preventing transmission of a sexually transmit

oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene gly

ted disease, the method comprising the step of administering

cols and fatty acid esters of sorbitol or mixtures thereof.

an effective amount of a compound of formula

The pharmaceutical compositions Will generally contain

In one

embodiment, the compound is administered topically to the

from about 0.0001 to 90 Wt. %, preferably about 0.01 to 10

vaginal cavity.

Wt. % of the active ingredient by Weight of the total
composition. In addition to the active agent, the pharma

By “sexually transmitted disease”, it is meant any com
municable disease transmitted by sexual intercourse or geni

ceutical compositions and medicaments can also contain

10

other pharmaceutically active compounds.
Any diluent in the pharmaceutical compositions of the

In the previous descriptions, numerous speci?c details are
set forth, such as speci?c materials, structures, chemicals,
processes, etc., in order to provide a thorough understanding

present invention may be any of those mentioned above in

relation to the pharmaceutical compositions.
In addition, the present invention relates to synergistic
pharmaceutical compositions Wherein the active agent is
complexed With polyvinylpyrrolidone (PVP). As a result of
the synergy betWeen the PVP and the compounds of formula
(I), solutions With small concentrations of the inventive

tal contact, for example, HIV, gonorrhea and syphilis.

15

of the present invention. HoWever, the present invention can
be practiced Without resorting to the details speci?cally set
forth. In other instances, Well knoWn processing structures
have not been described in detail in order not to unneces

sarily obscure the present invention.
20

compounds can be used, resulting in reduced vaginal irrita

EXAMPLE 1

tion.
The dosage rate, e.g., about 0.04 to about 100 mg/kg of
body Weight, such as about 0.01 to about 1 mg/kg Will be a
function of the nature and body Weight of the human to be
treated, the individual reaction of this subject to the

Synthesis of Mono-iodinated Nonoxynol-9
This example describes the synthesis of mono-iodinated
25

Mono-iodinated nonoxynol-9 (IN-9) Was prepared
through a series of chemical reactions using nonoxynol-9

treatment, type of formulation in Which the active ingredient
is administered, the mode in Which the administration is
carried out and the point in the progress of the disease or
interval at Which it is to be administered. Thus, it may in

(N-9) (Igepal CO-630) (Rhone-Poulenc, lot. SP6C057657)
as the starting material. Thallium tri?uoroacetate (TTFA)
30

some case suf?ce to use less than a minimum dosage rate,
While other cases an upper limit must be exceeded to achieve

the desired results. Where larger amounts are administered,
it may be advisable to divide these into several individual
administrations over the course of the day.

Nonoxynol-9.

(Aldrich Chemical Co., lot 02601KQ) (20.60 gm, 37.9
mmol) Was solubiliZed in tri?uoroacetic acid (TFA) (Fisher
Biotech, lot. 955483) (50 mL, 74 gm) to yield a light broWn
solution. N-9 (20.23 gm, 32.84 mmol) Was added to a 125

35

mL Erlenmeyer ?ask equipped With a magnetic stir bar. The
TTFA-TFA solution Was added dropWise over 10 minutes

Where it is desired to administer the compound vaginally,

into the Erlenmeyer ?ask containing N-9 While stirring and

a vaginal suppository may be prepared by mixing the active

keeping the reaction ?ask at room temperature and pressure.
At the onset of the addition, the solution contained in the
Erlenmeyer ?ask Was light broWn in color and gave Way to

constituents With at least one polyethylene glycol, the glycol
or mixture of glycols having a melting point at or beloW
body temperature. To facilitate the ef?cient dispersion of the
active ingredient in the vagina, the suppository may also
contain foam producing substances, such as sodium bicar
bonate and sodium phosphate, and, to assure long duration
of the foam, a foam stabiliZing agent, such as sodium lauryl

40

a dark broWn color over time. The solution Was stirred for an

additional 20 minutes to alloW the thallium species to react
45

of deioniZed Water and added dropWise to the ?ask contain
ing the N-9 solution over a period of ?ve minutes While
stirring. During the addition of the KI solution, a dull

sulfate can be used.

Alternatively, a sponge may be prepared by absorbing the
active constituents into a biocompatible, bioinsoluble, non

toxic sponge-like soft polymer Suitable polymers for this

50

use are Well knoWn in the art, and include, for example,

2-hydroxyethylmethacrylate.
Acream according to this invention may contain a hydro
carbon base, such as White petrolatum, a solvent, such as

neutraliZation point, the formed precipitate attained a ?ne,
granular appearance and Was bright yelloW in color. At this

point, the bright yelloW precipitate Was removed by suction
60

The present invention further relates to a method for

preventing conception, the method comprising the step of
administering an effective amount of a compound of formula

By “prevention of conception” it is meant that a viable
Zygote cannot be formed.

(Aldrich Chemical Co., lot. 06928T2) Was added until the
solution Was neutraliZed and brought to pH=8. Near the

Inventive formulations can be administered topically to

(I).

yelloW, globular precipitate Was formed in copious amounts.
Thereafter, sodium metabisul?te (Aldrich Chemical Co., lot.
11824HG) (5.01 gm, 26.35 mmol) Was added to the ?ask
and alloWed to stir for 10 minutes. A 10 M NaOH solution

55

glycerin or propylene glycol, and an emulsi?er, such as cetyl
alcohol.

the vaginal cavity for their local activity against human
spermatoZoa.

With N-9 completely.
Potassium iodide (KI) (Aldrich Chemical Co., lot
03330PN) (40.78 gm, 245.6 mmol) Was dissolved in 120 mL

65

?ltration using a Buechner funnel, No. 1 Whatman ?lter
paper and an Erlenmeyer ?lter ?ask.
The aqueous ?ltrate had a golden broWn appearance and
Was Washed With chloroform (Fisher Chemical Co., lot.

970035) (3 portions, 150 mL total) in a 250 mL separatory
funnel to extract the product. The collected chloroform

Washings Were Washed With deioniZed Water (2 portions,

US 6,281,251 B1
7

8

100 mL total) in a clean 250 mL separatory funnel. The

of approximately 60% Di-IN-9 and 40% of IN-9. Both the

Washed chloroform Was transferred to a 200 mL Erlenmeyer

iodide atoms in the Di-IN-9 Were expected to add at the

?ask and stirred for 4 hours With magnesium sulfate mono

ortho positions of the aromatic ring relative to the polyeth

hydrate (Aldrich Chemical Co., lot. 43418-3) to remove any
residual Water. A sintered glass funnel (10—15 pm pore siZe)

ylene oxide side chain. The Di-In-9 and IN-9 species Were

separated by HPLC using a preparative C-18 column
(Waters p-Bondapak, 19><300 mm, # M6179101) and a
mobile phase of 80% MeOH and 20% H2O. As shoWn in
FIG. 6, the H-NMR of the Di-IN-9 derivative revealed only

Was used to remove the magnesium sulfate from the solu
tion. The chloroform layer Was transferred to a 250 mL
round bottom ?ask to remove the solvent by reduced pres

sure at 60° C. leaving 22.74 gm (93.1% Weight recovery) of

10

a yelloW, viscous liquid. The iodine atom in IN-9 Was

expected to add at the ortho position of the aromatic ring
relative to the polyethylene oxide side chain. The general
arrangement of the synthesis of the mono-iodinated N-9
(IN-9) is shoWn in FIG. 1.

EXAMPLE 3
15

log1O of their partition coef?cients, for the inventive oligo
mers.

20

Bondapak, 3.9><300 mm, #P11061B40) With methanol/Water
(80:20) as a mobile phase. An ultraviolet (UV) detector set
at 280 nm alloWed for the detection of the product and
starting material. N-9 Was undetectable in the product
obtained using the above HPLC procedure and only one

25

region of the spectra from 6.7—7.5 ppm for IN-9 indicating
three chemically distinct protons on the ring. The appear

mining the solubiliZation of various membranes by nonionic
30

35

compounds.
EXAMPLE 2

40

Synthesis of Di-iodinated Nonoxynol-9
This example describes the synthesis of di-iodinated

Nonoxynol-9.
Di-iodinated Nonoxynol-9 (Di-IN-9) Was prepared using

of the entire molecule. The division product Was then

numbers denote more hydrophilic character. In studies deter

ance of three distinct protons veri?ed that an iodide atom

had replaced a proton on the aromatic ring of N-9. As shoWn
in FIG. 4, in this same region of the spectra, the spectra of
N-9 revealed only tWo distinct protons. These spectra Were
consistent With the expected structural formulas of the

A simple method of comparing structurally similar sur
factants can be performed by calculating the hydrophilic
lipophilic balance (HLB) of the compounds. This calcula
tion Was determined by dividing the molecular Weight of the
hydrophilic portion of the molecule by the molecular Weight
multiplied by 100 to give a percentage, then divided by 5 to
give an orderly range. For nonionic surfactants, higher HLB

peak, shoWn in FIG. 2, that of the mono-iodinated product,
Was observed. A H-NMR spectra, in CDCl3, alloWed for the
quanti?cation of protons located on the aromatic ring. As
shoWn in FIG. 3, three peaks Were detected in the aromatic

This example shoWs characteriZation data, including HLB
values, retention times on the normal HPLC system and the

Analysis of the resulting product indicated that virtually
all of the N-9 Was converted to the mono-iodinated species.
The analysis of the reaction product Was conducted by a
reverse phase HPLC assay using a C-18 column (Waters

one chemically distinct proton in the aromatic region at 7.6
ppm, Which is consistent With the expected structural for
mula.

45

chemical steps similar to those rendered to produce the

surfactants, the HLB range from 12.5—14.5 Was determined
to be the most effective surfactants2. The method of calcu

lating the HLB numbers Was employed in the comparison of
N-9, IN-9, Di-IN-9 and their constituent oligomers.
A normal phase HPLC system has been devised in order
to isolate the oligomers of N-9 and the iodinated derivatives
of N-9 for chemical characteriZation. The HPLC separation
of oligomers Was performed on the Waters system

(Millipore, Waters Chromatography, Millford, Mass.) that
included tWo Waters Model 510 pumps, a Waters 740 Data
Module, a Waters Lambda-Max Model 481 UV detector and
a Waters Automated Gradient Controller. The process used

the above HPLC system and a linear gradient solvent system
from 98% A-2% B to 50% A-50% B over ninety minutes at
a How rate of 9.9 mL/minute (A=hexane:tetrahydrofuran,

mono-iodinated species. In this synthetic procedure, the

80:20 v/v; B=2-propanol:Water, 90:10 v/v). A7-pm Zorbax

folloWing changes Were incorporated. The molar ratio of

NH2 preparative column (21.2><250 mm) (Rockland
Technologies, Inc.) Was used With the system for the sepa

TTFA to N-9 Was altered to alloW for the additions of tWo

TTFA molecules per aromatic ring of N-9 (2.16 moles of
TTFA to 1 mole of N-9). The dropWise addition of the

50

ration process. A Waters solvent fraction collector Was
programmed so that the effluent could be collected every

sixty seconds betWeen 15 and 80 minutes after the injection

TTFA/TFA solution to N-9 Was conducted in a 100 mL

round bottom ?ask With stirring. Upon the completion of the

of the product onto the column. The UV detector Was set at
addition of the TTFA/TFA solution to N-9, the mixture Was 55 280 nm to detect the oligomers therefore alloWing a trace of
heated to 60° C. With a condenser in place for 24 hours While
the effluent to be made to determine Which time points
Would be combined. The solvent of the fractions of interest
stirring. The amount of sodium metabisul?te Was increased

Was evaporated and the oligomer identify determined by

(10.10 gm, 53.13 mmol) in order to compensate for the
increased amount of TTFA in the reaction. OtherWise, the
chemical steps and the molar ratios used Were precisely the
same as those performed in the synthesis of the mono

FAB mass spectrometry.
60

iodinated species, described above. The general arrangement
of the synthesis of di-iodinated N-9 (Di-IN-9) is shoWn in
FIG. 5.

Analysis of the Di-IN-9 product, using the same reverse
HPLC procedure mentioned previously, revealed a mixture

65

A FAB mass spectral analysis alloWed for the identi?ca
tion of each fraction collected. The fraction believed to be
the oligomer n=7 Was used to determine the molecular

Weight for identi?cation purposes. The calculated molecular
Weight of n=7 for N-9, IN-9 and Di-IN-9 Were 528.7, 654.6
and 780.5 respectively. After subtraction of the mass of a

potassium ratio (K’'), the mass spectral analysis revealed

US 6,281,251 B1
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molecular Weight values of 528.3, 654.2, and 779.9 for the
n=7 oligomer of N-9, IN-9 and Di-IN-9 respectively (shown
in FIGS. 7, 8 and 9). Once identi?ed, the oligomers Were
characterized by their molecular Weights, HLB values,
retention times on the normal HPLC system and the log1O of

10
TABLE 1
Hydrophilic-lipophilic balance (HLB), chromatographic mobility, and
partition coefficients of selected oligomers of N-9 versus the
5

mono-iodinated nonoxynol-9 (IN-9).

Nonoxynol-9 (N-9)

their partition coefficients.
The experimental calculation of the log of the partition
coefficient values (log P) indicated that iodinated
nonoxynol-9 Was more lipophilic relative to nonoxynol-9

(see Table 1). Radiolabeled species ([14C]nonoxynol-9,

determined that the halogens (F, Cl, Br, I), When attached

398
574
706
794

23.9
44.2
60.3
70.0

I
I
I
I

0.5
0.7
0.4
0.4

HLBb

log PC

9.7
12.9
14.2
14.9

1.6 I 0.05
1.4 I 0.01
1.3 I 0.07
ND"

# of E0.

Molecular Wt.

4
8
11
13

524
701
833
921

Rt“

HLBb

log P(1

23.5
43.6
59.4
68.5

I
I
I
I

0.4
0.4
0.3
0.3

7.4
10.5
12.1
12.8

2.4
2.2
2.2
1.8

I
I
I
I

0.2
0.1
0.1
0.1

*[14C]N—9 sample (commercial) contained no N-9 (n = 13) oligomer.
aHPLC retention time by Zorbax-NH2 preparative column (min, mean :
S.D., n = 10 for N-9, n = 12 for IN-9).

bhydrophilic-lipophilic balance (HLB), calculated as the molecular Weight
of the hydrophilic moiety (polyethylene oxide chain of N-9) divided by

polariZation by solvent molecules, therefore increasing its

lipophilic character on a molecule (n=log PSubSn-med molecule

4
8
11
13

Rt“

15

covalently to an aromatic ring, WithdreW a portion of the
electron density out of the ring. The decrease in electron
density causes the ring to be less susceptible to induced

lipophilic character. The hydrophobic parameter at, devel
oped by Hansch, re?ects a substituent’s ability to impart

Molecular Wt.

Mono-iodinated Nonoxynol-9 (IN-9)

[125I]iodinated nonoxynol-9) Were used to obtain precise
measurements of the log P values. Iodinated nonoxynol-9
Was conceptualiZed to be more lipophilic based upon the
Work by chemists such as Hammett and Hansch. Hammett

# of E0.

the molecular Weight of the Whole molecule times 100 and the product is
further divided by ?ve to have a scale of O-20. (Remington’s Pharmaceu
25 tical Sciences, 18th edition, p. 304, 1990)

Cpartition coe?icient in n-octanol/Water, as determined by [14C]N—9
dpartition coef?cient in n-octanol/Water, as determined by 1Z5IN-9

log PunSubSn-med molecule). Hansch found experimentally that
the halogens created a positive at value in most molecular
systems Which correlated With an increase in the lipophilic

EXAMPLE 4

Assessment of Spermicidal and Anti-HIV

ity of the compound. With iodinated nonoxynol-9 possess
ing greater lipophilic character, the ethylene oxide chain can

Properties
N-9 and its iodinated derivatives Were assessed in vitro

be lengthened to maintain the proper HLB. Additionally, the

lengthening of the ethylene oxide chain alloWs for reduced

for their ability to kill spermatozoa and HIV virions. The

irritation of the vaginal epithelial lining by reducing the
formation of micelles. Nonoxynols With larger ethylene

Sander-Cramer assay Was performed in order to evaluate the
35

tates With PVP. This assay determines the minimum lethal

oxide chains have been shoWn to cause less hemolysis in

dose, reported as a concentration, of spermicide needed to

erythrocytes during in vitro irritation studies. Iodide Was
chosen as the halogen to substitute nonoxynol-9 due to its
relatively large (I and at values it produces When employed

kill all spermatoZoa Within tWenty seconds. The folloWing
oligomers Were incorporated into coprecipitates With PVP
for the in vitro assessment: IN-9 (n=1—17), IN-9 (n=8) and

as a substituent. With an increase in the hydrophobic

IN-9 (n=13). The neat liquids of N-9 and IN-9 Were also

character, iodinated nonoxynol-9 should insert into sperm

assessed for their spermicidal activity. The quantity of active

membranes more readily leading to an increase in spermi

cidal activity. In addition, the molecular Weight and siZe of
iodinated nonoxynol-9 is greater than that of nonoxynol-9
Which leads to the possibility of the molecule being less

compound in each coprecipitate Was determined by a normal
45

bioavailable from vaginally placed dosage forms.

effective concentration (MEC) needed to exhibit complete
spermicidal activity for the neat liquid of IN-9 (n=1—17)
(MEC-6.0 pg/mL) is over 30 times less than that needed for

oxide units (n=4, 8, 11, and 13). The oligomer of N-9 (n=8)
Was chosen since it Was found to be the most abundant
55

that of N-9 (n=8) (HLB=12.90). The oligomers of n=4 and

the neat compound N-9 (n=1—17) (see Table #2). The
coprecipitates of IN-9 (n=8) (MEC=94 pg/mL) and IN-9

n=11 Were chosen for the characteriZation of a lipophilic

oligomer and an additional hydrophilic oligomer. The HLB
values of the entire mixture of oligomers of N-9, IN-9 and
Di-IN-9 Were calculate using a Weighted computation.

(n=13) (MEC=23 pg/mL) presented signi?cantly different
spermicidal potencies When compared to N-9 (n=1—17),
suggesting that isolation of a single oligomer may be a
feasible route to increase spermicidal action While decreas

Using this calculation, IN-9 (n=1—17) (HLB=10.56) and
Di-IN-9 (n=1—17) (HLB=9.01) Were theoriZed to be more

to compare their chemical and physical characteristics.

the neat liquid of N-9 (n=1—17) (MEC=188.0 pg/mL). The
MEC values indicate that the neat compound IN-9 (n=1—17)
is 30 times more effective in killing human spermatoZoa than

selected since its calculated HLB value Was most similar to

lipophilic in character than N-9 (n=1—17) (HLB=12.80).
Samples of N-9, [14C]N-9, IN-9 and 125IN-9 Were separated

phase HPLC analysis and presented as a Weight by Weight
(W/W) percentage. The amount of active compound in each
coprecipitate Was adjusted by using the W/W percentages so
that the assays Were conducted using equimolar amounts of
active compounds. The results of the Sander-Cramer assays
are shoWn in Table #2. The results indicate that the minimum

At this time, the characteriZation of the oligomers of
Di-IN-9 has not been completed. The oligomers of interest
for comparison Were those With 4, 8, 11 and 13 ethylene

oligomer in the mixture“. IN-9 (n=13) (HLB=12.83) Was

spermicidal activity of the surfactants and their coprecipi

65

ing irritation potential.
The compounds used in the Sander-Cramer assays (neat
liquids and coprecipitates) Were evaluated for their anti-HIV

US 6,281,251 B1
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12

activity using the Cell-Free and Cell-Associated Inactivation

Acosta, Anibal A. and Kruger, Thinus F. (eds.) Human
Spermatozoa in Assisted Reproduction, pp. 172—192.

Assays (see Table #3). Both assays employ solutions of

(NeW York: The Parthenon Publishing Group).

active compound at varying concentrations in order to detect
the optimal concentration to reduce the infectivity of a

. Helenius, Ari and Simons, Kai (1975). solubiliZation of

Membranes by Detergents, Biochimica et Biophysica
Acta, 415, pp. 29—79. (Amsterdam: Elsevier Publishing

redetermined HIV viral load in the form of free HIV-1-RF or 5

Company).

RF infected H9 cells. A solution of active compound is
determined to have sufficient anti-viral activity if, When

. Shachat, Norman and GreenWald, Harold L. (1967).

Mechanism of Ethylene Oxide Condensation. Schick,
Martin J. (ed.) N0ni0nic Surfactants, pp. 8—42. (NeW
York: Marcel Dekker, Inc.).

tested, a viral titer reduction of at least tWo log1, units
occurs. N-9 and IN-9, in their neat liquid forms, Were both 10
found to be virucidal against cell-free and cell-associate
HIV. It Was determined that IN-9 (n=1—17) is at least as

. Walter, Brian A. and Digenis, George A. (1991). High

Performance Liquid Chromatographic (HPLC) Analysis
of Oligomeric Components of the Spermicide
Nonoxynol-9. Pharmaceutical Research, 8, pp. 409—411.

effective in killing HIV as N-9 (n=1—17) (see Table #3).
Furthermore, IN-9 appears to be slightly more effective than
N-9 against cell-associated HIV Which appears to be the
predominant form of HIV in male to female transmission via

. Walter, Brian A., HaWi, Amale A., Zavos, Panayiotis M.,
and Digenis, George A. (1991). SolubiliZation and in
Vitro Spermicidal Assessment of Nonoxynol-9 and
Selected Fractions Using Rabbit SpermatoZoa. Pharma
ceutical Research, 8, pp. 403—408.

sexual intercourse. The coprecipitates of N-9 (n=1—17) and
IN-9 (n=1—17) Were also virucidal in both assays.
TABLE 2
Spermicidal Activity Results
Sander-Cramer Assay

Highest
Solvent

(‘ug/mL)

N-9
Equimolar
(‘ug/mL)

dH2O
dH2O
dH2O
dH2O
dH2O

24
29
386
545
555

24
24
24
24
24

Initial Conc.

Compound
N-9 (1-17)
IN-9 (1-17)
IN-9 (1—17)/PVP
IN-9 (8)/PVP
IN-9 (13)/PVP

Spermicidal
Dilution,
median

(‘ug/mL)

n

Solubility

128.0
4096.0
2048.0
256.0
1024.0

188.0
6.0
12.0
94.0
23.0

17
17
17
17
17

OK
OK
OK
OK
OK

17 OK clear soln. pH 6.5, 6.5

M.E.C.

N-9 (1—17)*

dH2O

24

24

128.0

188.0

PVP

dH2O

100

0

FAILED

N/A

3

clear soln. ph 6.5, 7.0#
hazy soln. pH 7.0, 7.5
haZy soln. pH 5.0, 5.0
hazy soln. pH 5.5, 5.5
cloudy soln. pH 5.0, 5.5

OK

*Commercial control; #TWo pH determinations
N-9 = Nonoxynol-9; IN-9 = Mono-iodinated nonoxynol-9; PVP = Polyvinylpyrrolidone; M.E.C. = Minimum effective concentration;
Conc. = Concentration; Soln. = Solution; n = Number of determinations

TABLE 3
Anti-HIV Activity Assessment in Cell-Free and Cell-Associated Viral Inactivation Assays
Cell-Free HIV Inactivation

Compound

Solvent

Date

N-9 (1-17)

dH2O

02/25/98

IN-9 (1-17)

dH2O

02/25/98

Conc. (%)

dH2O

02/25/98

Infec. Red. (log)*

Date
04/16/98

0.1

>3.5

0.032
0.01
0.0032

>4.5
2.3
0.3

0.1

>4.5

0.032
0.01
0.0032

Positive Control

Cell-Associated HIV Inactivation

0.1
0.032
0.01
0.0032

04/16/98

3.3
2.3
0.3

Conc. (%)
0.1

3.2

0.032
0.01
0.0032

2.5
0.8
0.8

0.1
0.032
0.01
0.0032

>3.5

04/16/98

4.3
1.5
0.0

Infec. Red. (log)*

0.1
0.032
0.01
0.0032

>5.0
2.3
1.8
1.0

>5.0
1.7
1.0
0.7

*Indicates reduction of infectious viral titer of HIV-1-CF stock after a tWo minute incubation With the compound (reported in log

units).

Only the preferred embodiment of the present invention and an example of its versatility are shoWn and described in the present disclo
sure. It is to be understood that the present invention is capable of use in various other combinations and environments and is capable
of changes or modi?cations Within the scope of the inventive concept as expressed herein.

6. Digenis, George A. and Digenis, Alexander G. (1995).
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What is claimed is:
1. A compound of the formula:

15. The composition according to claim 12, in a form

suitable for vaginal application.

a cap diaphragm.

30

17. Aprocess for preparing a compound of claim 1 of the
formula:
I

35

R

O—(-CH2CH2O j,,—H

Q

40 Wherein R is a carbon atom containing moiety having at least

6 carbon atoms, Q is I, and n=1—25, comprising the steps of:
(a) reacting thallium tri?uoroacetate With a compound of

Wherein R is a carbon atom containing moiety having at least
6 carbon atoms, Q is I, and n=1—25.

2. The compound according to claim 1, Wherein n=8.
3. The compound according to claim 1, Wherein n=9.
4. The compound according to claim 1, Wherein n is from

formula:
45

4 to 15.

5. The compound according to claim 4, Wherein n is 6—8.
6. The compound according to claim 5, Wherein n=6.
7. The compound according to claim 1, Wherein n=7.
Wherein Q and n are as de?ned above to form an electro
8. The compound according to claim 1, Which is Water
philic thallium intermediate,
soluble.
(b) iodinating the intermediate to form a monoiodinated
9. The compound according to claim 1, Which is Water
intermediate in the ortho-position;
insoluble.
55
(c) then further reacting With additional thallium tri?uo
10. The compound according to claim 1, Wherein one or
racetate to form a monoiodinated electrophilic thallium
both iodine atoms are radioisotopes, and the iodine radio
intermediate; and
isotopes are selected from the group consisting of 123
(d) reacting the intermediate With additional iodonatino
iodine, 125-iodine and 131-iodine.
6O
reactant to form a compound of claim 1.
11. The compound according to claim 1, Wherein R is
18. The process of claim 17, further comprising:
nonyl or octyl.
isolating at least one iodinated oligomer.

12. Apharmaceutical composition comprising an effective
amount of a compound of the formula:

*

*

*

*

*

